![](/images/graphics-bg.png)
A “Stadium” urticaria, cold urticaria is still a mostly unknown disease, with a wide spectrum of severity degrees and few therapeutic certainties : is omalizumab one of these ? reflections from a clinical case report
Joint Authors
Martinis, Massimo De
Sirufo, Maria Maddalena
Ginaldi, Lia
Source
Iranian Red Crescent Medical Journal
Issue
Vol. 21, Issue 1 (31 Jan. 2019), pp.1-8, 8 p.
Publisher
Publication Date
2019-01-31
Country of Publication
United Arab Emirates
No. of Pages
8
Main Subjects
Topics
Abstract EN
Introduction: One of the most common forms of physical urticaria is the cold urticaria.
It can be a medical emergency, since it can induce anaphylaxis and edema of the glottis, and in any case, it is a condition that reduces the quality of life of the affected subjects forced to significantly limit their normal activities.
Moreover, since the symptoms are triggered by exposure to cold, which is difficult (if not impossible) to avoid in everyday life, a safe and effective therapy appears to be essential.
Unfortunately, traditional therapies often cannot provide adequate and safe answers.
Case Presentation: The current study reported the case of a 52-year-old female patient manifesting the first symptoms after going to the stadium to watch football games while sitting in the stands.
On such occasions, her buttocks would begin to itch, and started swelling and reddening.
These manifestations then occurred on other occasions of exposure to the cold, and in other body areas.
The patient visited the outpatient clinic of Allergy and Clinical Immunology Unit, Teramo General Hospital (Teramo, Italy), and was treated with sedating and non-sedating H1-blocking antihistamines (Rupatadine, Cetirizine), a leukotriene antagonist, and oral steroids with no success; therefore, it was decided to treat her with Omalizumab, an anti-IgE antibody.
Conclusions: The satisfactory response to Omalizumab in the patient, after the failure of previous standard therapeutic strategies, confirmed the effectiveness of this molecule to treat cold urticaria, which despite what reported in several studies, is not yet recognized and authorized by the competent health authorities in the treatment of this condition.
American Psychological Association (APA)
Martinis, Massimo De& Sirufo, Maria Maddalena& Ginaldi, Lia. 2019. A “Stadium” urticaria, cold urticaria is still a mostly unknown disease, with a wide spectrum of severity degrees and few therapeutic certainties : is omalizumab one of these ? reflections from a clinical case report. Iranian Red Crescent Medical Journal،Vol. 21, no. 1, pp.1-8.
https://search.emarefa.net/detail/BIM-883638
Modern Language Association (MLA)
Martinis, Massimo De…[et al.]. A “Stadium” urticaria, cold urticaria is still a mostly unknown disease, with a wide spectrum of severity degrees and few therapeutic certainties : is omalizumab one of these ? reflections from a clinical case report. Iranian Red Crescent Medical Journal Vol. 21, no. 1 (Jan. 2019), pp.1-8.
https://search.emarefa.net/detail/BIM-883638
American Medical Association (AMA)
Martinis, Massimo De& Sirufo, Maria Maddalena& Ginaldi, Lia. A “Stadium” urticaria, cold urticaria is still a mostly unknown disease, with a wide spectrum of severity degrees and few therapeutic certainties : is omalizumab one of these ? reflections from a clinical case report. Iranian Red Crescent Medical Journal. 2019. Vol. 21, no. 1, pp.1-8.
https://search.emarefa.net/detail/BIM-883638
Data Type
Journal Articles
Language
English
Notes
Includes appendices : p. 8
Record ID
BIM-883638